Dr. Garassino Discusses Promising Findings With Osimertinib for Patients With NSCLC and Brain Mets

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses a subset analysis of the AURA3 trial, which demonstrated significant clinical activity with osimertinib (Tagrisso) for patients with EGFR T790M-mutation positive non–small cell lung cancer (NSCLC) who also harbor brain metastases.

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses a subset analysis of the AURA3 trial, which demonstrated significant clinical activity with osimertinib (Tagrisso) for patients with EGFR T790M-mutation positive non—small cell lung cancer (NSCLC) who also harbor brain metastases.

Related Content:

ASCO Annual MeetingConferenceLung Cancer
Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma
Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma
IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma